Bupivacaine Hydrochloride-EPINEPHrine

Phase 1Small molecule

Bupivacaine Hydrochloride-EPINEPHrine is one of 10 small molecule programs targeting Opioid. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OpioidEnrolling by invitation

OpioidPhase 1

Enrolling by invitation

Competition

Competitive Landscape

12 competitors in Opioid

#DrugCompanyPhaseTrials

Oxycontin

PProtega

Phase 3

4 2

Revia

Teva

Phase 2

6 3

Epidiolex

Jazz Pharmaceuticals

Phase 2

1 4

Suboxone

Merck & Co.

Phase 3

1 5

Narcan

SScienture

Phase 1

7 6

DOVATO

GSK

Phase 3

1 7

Alfenta

Jazz Pharmaceuticals

Preclinical

1 8

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 9

Imodium

KKenvue Brands

Phase 1

1 10

Bupivacaine Hydrochloride-EPINEPHrine

UUniversity of Missouri-Columbia

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Opioid1 trial

Exparel Injection Effect on Postoperative Opioid Usage

Enrolling by invitation·UUniversity of Missouri-Columbia·Phase 1·NCT04085913·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bupivacaine Hydrochloride-EPINEPHrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bupivacaine Hydrochloride-EPINEPHrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bupivacaine Hydrochloride-EPINEPHrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Missouri-Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Missouri-Columbia

Bupivacaine Hydrochloride-EPINEPHrine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Opioid1 trial

References

Drug Info

Quick Facts

Related News